Related Experiment Video
Updated: Jun 10, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America
Michelle Weisfelner Bloom1, Jacqueline B Vo2, Jo E Rodgers3
1Division of Cardiology, NYU Langone Health, NYU Grossman School of Medicine, New York, NY.
Insights
Heart failure and cancer care require specialized knowledge. This statement guides healthcare professionals in managing heart failure in cancer patients, addressing cardiotoxicity and improving outcomes.
Area of Science:
- Cardio-oncology
- Cardiovascular Medicine
- Oncology
Background:
- Heart failure and cancer are leading causes of death.
- Cancer therapies can cause cardiovascular complications.
- Cardiomyopathy in cancer patients indicates poor prognosis.
Purpose of the Study:
- To provide guidance on heart failure management in cancer patients.
- To address prevention, risk stratification, diagnosis, and management of cardiotoxicity.
- To highlight shared risk factors and multidisciplinary care.
Main Methods:
- Review of current literature and clinical practices.
- Development of a framework for cardio-oncology care.
- Discussion of heart failure stages, preserved ejection fraction, and special populations.
Main Results:
- Cancer patients face increased cardiovascular risks from therapies.
- Heart failure is a significant cardiotoxicity associated with cancer treatments.
- Shared risk factors between cancer and heart failure exist.
Conclusions:
- Cardio-oncology requires a multidisciplinary approach involving heart failure, oncology, and other specialists.
- Effective management strategies are crucial for patients with cancer and heart failure.
- Addressing disparities in care is essential for this complex patient group.
Abstract:
Heart failure and cancer remain 2 of the leading causes of morbidity and mortality, and the 2 disease entities are linked in a complex manner. Patients with cancer are at increased risk of cardiovascular complications related to the cancer therapies. The presence of cardiomyopathy or heart failure in a patient with new cancer diagnosis portends a high risk for adverse oncology and cardiovascular outcomes. With the rapid growth of cancer therapies, many of which interfere with cardiovascular homeostasis, heart failure practitioners need to be familiar with prevention, risk stratification, diagnosis, and management strategies in cardio-oncology. This Heart Failure Society of America statement addresses the complexities of heart failure care among patients with active cancer diagnoses and cancer survivors. Risk stratification, monitoring and management of cardiotoxicity are presented across stages A through D heart failure, with focused discussion on heart failure with preserved ejection fraction and special populations, such as survivors of childhood and young-adulthood cancers. We provide an overview of the shared risk factors between cancer and heart failure, highlighting heart failure as a form of cardiotoxicity associated with many different cancer therapeutics. Finally, we discuss disparities in the care of patients with cancer and cardiac disease and present a framework for a multidisciplinary-team approach and critical collaboration among heart failure, oncology, palliative care, pharmacy, and nursing teams in the management of these complex patients.
More Related Videos
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology
Heart Failure I: Introduction
Heart Failure III: Clinical Manifestations
Heart Failure V: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation

